Science Stories
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Idiopathic hypersomnia (IH) is a debilitating neurologic sleep disorder characterized by chronic excessive daytime sleepiness. Despite the physical and mental impact of the condition, the road to diagnosis and appropriate treatment can be long and filled with challenges.
Those who have recently heard the words ’you have cancer’ or ’we need to start you on a treatment regimen right away’ may have experienced overwhelming feelings around the extensive list of possible side effects from treatment.
While the oncology community is large, Actelion focuses on smaller groups of people facing unique challenges and difficult odds, such as those living with small cell lung cancer (SCLC). In the U.S., approximately 13 percent of lung cancers are small cell and nearly 30,000 new cases of SCLC are recorded in the U.S. every year.